Yvonne Pak

882 total citations
17 papers, 534 citations indexed

About

Yvonne Pak is a scholar working on Hematology, Radiology, Nuclear Medicine and Imaging and Genetics. According to data from OpenAlex, Yvonne Pak has authored 17 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Genetics. Recurrent topics in Yvonne Pak's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Platelet Disorders and Treatments (3 papers). Yvonne Pak is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Platelet Disorders and Treatments (3 papers). Yvonne Pak collaborates with scholars based in United States and United Kingdom. Yvonne Pak's co-authors include Michael Mayersohn, Uma Sinha, Francis DeGuzman, Stanley J. Hollenbach, Anjali Pandey, Greg Coffey, Dale C. Baker, Mayuko Inagaki, Tarundeep Kakkar and Nisha Nanda and has published in prestigious journals such as Circulation, Blood and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Yvonne Pak

17 papers receiving 519 citations

Peers

Yvonne Pak
Bo Jiao China
Kōjirō Yasunaga Japan
Mark Wade United States
Naoaki Murao Japan
J Bouguet France
Lijia Chen China
Hassan A. Hamali Saudi Arabia
Dennis A. Noe United States
Feng Bai United States
Xuelan Zuo China
Bo Jiao China
Yvonne Pak
Citations per year, relative to Yvonne Pak Yvonne Pak (= 1×) peers Bo Jiao

Countries citing papers authored by Yvonne Pak

Since Specialization
Citations

This map shows the geographic impact of Yvonne Pak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yvonne Pak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yvonne Pak more than expected).

Fields of papers citing papers by Yvonne Pak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yvonne Pak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yvonne Pak. The network helps show where Yvonne Pak may publish in the future.

Co-authorship network of co-authors of Yvonne Pak

This figure shows the co-authorship network connecting the top 25 collaborators of Yvonne Pak. A scholar is included among the top collaborators of Yvonne Pak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yvonne Pak. Yvonne Pak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Chari, Ajai, Sarah M. Larson, Beata Holkova, et al.. (2018). Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leukemia & lymphoma. 59(11). 2588–2594. 20 indexed citations
2.
Coffey, Greg, Aradhana Rani, Yvonne Pak, et al.. (2016). PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. The Journal of Clinical Pharmacology. 57(2). 194–210. 15 indexed citations
3.
Coffey, Greg, Francis DeGuzman, Yvonne Pak, et al.. (2014). The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer. Journal of Pharmacology and Experimental Therapeutics. 351(3). 538–548. 73 indexed citations
4.
Spurgeon, Stephen E., Greg Coffey, Luke B. Fletcher, et al.. (2012). The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia. Journal of Pharmacology and Experimental Therapeutics. 344(2). 378–387. 40 indexed citations
5.
André, Patrick, Francis DeGuzman, Helena Haberstock-Debic, et al.. (2011). Thienopyridines, but Not Elinogrel, Result in Off-Target Effects at the Vessel Wall That Contribute to Bleeding. Journal of Pharmacology and Experimental Therapeutics. 338(1). 22–30. 21 indexed citations
6.
Coffey, Greg, Francis DeGuzman, Mayuko Inagaki, et al.. (2011). Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics. 340(2). 350–359. 91 indexed citations
7.
Reilly, Michael P., Uma Sinha, Scott M. Taylor, et al.. (2010). PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. 117(7). 2241–2246. 100 indexed citations
8.
Coffey, Greg, Mayuko Inagaki, Yvonne Pak, et al.. (2010). Specific Inhibition of Syk Suppresses Leukocyte Immune Function and Alleviates Inflammation In Rodent Models of Rheumatoid Arthritis. Blood. 116(21). 1727–1727. 2 indexed citations
9.
Reilly, Michael P., Uma Sinha, Scott M. Taylor, et al.. (2008). PRT060318, a Novel Syk Inhibitor, Prevents Heparin-Induced Thrombocytopenia in a Transgenic Mouse Model. Blood. 112(11). 269–269. 2 indexed citations
10.
André, Patrick, Pamela B. Conley, Francis DeGuzman, et al.. (2008). Abstract 1718: Combination of Direct Acting FXa Inhibitor and P2Y 12 Antagonist at Non-Effective doses Provides Significant Inhibition of Arterial Thrombosis. Circulation. 118(suppl_18). 1 indexed citations
11.
Sinha, Uma, Susan Edwards, Paul Wong, et al.. (2006). Antithrombotic Activity of PRT54021, a Potent Oral Direct Factor Xa Inhibitor, Can Be Monitored Using a Novel Prothrombinase Inhibition Bioassay.. Blood. 108(11). 907–907. 8 indexed citations
12.
Abe, Keith, Susan Edwards, Pei Lin, et al.. (2006). Animal Models of Thrombosis Help Predict the Human Therapeutic Concentration of PRT54021, a Potent Oral Factor Xa Inhibitor.. Blood. 108(11). 901–901. 20 indexed citations
13.
Pak, Yvonne, et al.. (2005). A porcine model for fixed drug eruptions in humans: the case of antipyrine in the Yucatan micropig. Journal of Applied Toxicology. 26(1). 1–4. 2 indexed citations
14.
Tang, Huadong, Yvonne Pak, & Michael Mayersohn. (2004). Protein expression pattern of P–glycoprotein along the gastrointestinal tract of the yucatan micropig. Journal of Biochemical and Molecular Toxicology. 18(1). 18–22. 22 indexed citations
15.
Pak, Yvonne, et al.. (2003). Sensitive and rapid isocratic liquid chromatography method for the quantitation of curcumin in plasma. Journal of Chromatography B. 796(2). 339–346. 69 indexed citations
16.
Kakkar, Tarundeep, Yvonne Pak, & Michael Mayersohn. (2000). Evaluation of a Minimal Experimental Design for Determination of Enzyme Kinetic Parameters and Inhibition Mechanism. Journal of Pharmacology and Experimental Therapeutics. 293(3). 861–869. 31 indexed citations
17.
Sukbuntherng, Juthamas, et al.. (1996). Characterization of the Properties of Cocaine in Blood: Blood Clearance, Blood to Plasma Ratio, and Plasma Protein Binding. Journal of Pharmaceutical Sciences. 85(6). 567–571. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bo Jiao Breakdown of academic impact, for papers by Kōjirō Yasunaga Breakdown of academic impact, for papers by Mark Wade Breakdown of academic impact, for papers by Naoaki Murao Breakdown of academic impact, for papers by J Bouguet Breakdown of academic impact, for papers by Lijia Chen Breakdown of academic impact, for papers by Hassan A. Hamali Breakdown of academic impact, for papers by Dennis A. Noe Breakdown of academic impact, for papers by Feng Bai Breakdown of academic impact, for papers by Xuelan Zuo
Rankless by CCL
2026